TARC: Turkish aripiprazole consensus report- Aripiprazole use and switching from other antipsychotics to aripiprazole- consensus recommendations by a Turkish multidisciplinary panel


VEZNEDAROĞLU B., Dilbaz N., Uzun O., Isik E.

THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, vol.8, no.10, pp.271-285, 2018 (Peer-Reviewed Journal) identifier identifier

  • Publication Type: Article / Review
  • Volume: 8 Issue: 10
  • Publication Date: 2018
  • Doi Number: 10.1177/2045125318772712
  • Journal Name: THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY
  • Journal Indexes: Science Citation Index Expanded
  • Page Numbers: pp.271-285

Abstract

In this review, we have attempted to share our 10 years' clinical experience with aripiprazole use and switching from other antipsychotics to aripiprazole. There are various reasons for switching, including a partial or complete lack of efficacy, adverse side effects, and partial or noncompliance with medication. Aripiprazole has some unique receptor-binding qualities that provides some advantages over other antipsychotics in certain clinical situations. We have covered potential clinical scenarios for aripiprazole use as a single agent and switching from other agents in inpatient and outpatient settings. Patients switched from other antipsychotics to aripiprazole have been shown to benefit from significant improvements in clinical response and tolerability. This review examines the strategies for switching patients from antipsychotic drugs to aripiprazole.